Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 13/20 | 0.50 |
| ▸ | PIK3R1 | P27986 | 10/20 | 0.50 |
| ▸ | MTOR | P42345 | 4/20 | 0.50 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24074637 | 1.00 | PIK3CA (0.50) | PIK3CAPIK3R1MTORPIK3CDPIK3CB | |
| SCHEMBL29057004 | 0.83 | KDM4E (0.43) | PIK3CAPIK3R1MTOR | |
| SCHEMBL31086781 | 0.80 | MTOR (0.45) | PIK3CAPIK3R1MTORPIK3CDPIK3CB | |
| SCHEMBL31006819 | 0.80 | MTOR (0.49) | PIK3CAPIK3R1MTORPIK3CDPIK3CB | |
| SCHEMBL31006818 | 0.80 | MTOR (0.49) | PIK3CAPIK3R1MTORPIK3CDPIK3CB | |
| SCHEMBL19959253 | 0.79 | ADORA1 (0.48) | MTORMAPTADORA1 | |
| SCHEMBL30338938 | 0.79 | ADORA1 (0.48) | MTORMAPTADORA1 | |
| SCHEMBL441537 | 0.78 | MTOR (0.59) | PIK3CAPIK3R1MTORPIK3CDPIK3CB | |
| SCHEMBL22718259 | 0.78 | MTOR (0.59) | PIK3CAPIK3R1MTORPIK3CDPIK3CB | |
| SCHEMBL24955676 | 0.77 | MTOR (0.57) | PIK3CAPIK3R1MTORPIK3CDPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-29 | — | — | US | disclosed |
| CN-116472292-A | Modified proteins and protein degrading agents | 上海睿跃生物科技有限公司 | 2023-07-21 | — | — | CN | disclosed |
| EP-4157888-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | Cullgen (Shanghai), Inc. (CN) | 2023-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | DDB1, DCLRE1A, MDM2 | PIK3CA 4237/4885PIK3R1 3108/4885MTOR 1772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.